.RESEARCH EMPHASIZE.16 October 2024.
In the NIAGARA trial, the addition of perioperative durvalumab to conventional therapy for muscle-invasive sac cancer cells enhanced event-free and on the whole survival, noting a brand-new treatment option for this condition.